Nxera Pharma Co., Ltd.
Notice of Revision to Earnings Forecast for the Fiscal Year Ending December 2026
Revised consolidated earnings forecast for the fiscal year ending December 2026. Revenue is forecast at 48,800 million yen, core operating profit at 22,800 million yen, and operating income at 15,700 million yen. Assumes receipt of a $100 million USD upfront payment, recognized as revenue. Previous upper-bound forecast has been adjusted to a specific value; foreign exchange assumption is 1 USD = 157.8 yen. Completion of the transaction and auditor agreement are conditions precedent.
Key Figures
- Revenue: 48,800 million yen
- Core Operating Profit: 22,800 million yen
- Operating Income: 15,700 million yen
AI要約
Revision of Earnings Forecast and Background
The revised consolidated earnings forecast for the fiscal year ending December 2026 published today assumes receipt of a $100 million USD upfront payment under an exclusive license agreement between subsidiary Nxera Pharma UK Ltd and AbbVie Inc. The foreign exchange assumption is 1 USD = 157.8 yen. Revenue is expected to be 48,800 million yen, core operating profit 22,800 million yen, and operating income 15,700 million yen, with the previous upper bound revised to a specific value. The revision is subject to completion of the transaction and agreement with the auditor; if completion is delayed or the assumptions change, we will disclose updates.
Impact on Business Strategy and Outlook
Through partnerships leveraging Nxera Pharma’s pipeline, including its EP4 agonist program, we intend to expand global revenue opportunities. The accounting treatment for the upfront payment will be to recognize it as revenue in the fourth quarter of the fiscal year ending December 2026, which is expected to contribute to future business revenue growth. However, if the transaction conditions are not met or the foreign exchange assumptions change, we may revise the earnings forecast again.
Nxera Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
